BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Nosology
,
Clofibrate
,
rs4950928
,
ERBB2
,
nitric oxide metabolic process
,
Leukemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PERK's kinase
Summary
General Info
Curated Studies
Most Correlated Studies
Prostate cancer LNCaP cells with PERK or ATF4 siRNA knockdown treated with tunicamycin
Endoplasmic reticulum stress in PERK liver specific knockouts
Translational response following activation of GCN2 or PERK
Primary hepatocytes treated with diclofenac
Hepatocellular carcinoma HepG2 cells, a model of drug induced liver injury
Explore Curated Studies Results
Literature
Most Relevant Literature
Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells vi…
PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation,…
Activation of PERK signaling through fluoride-mediated endoplasmic reticulum stress in OS732 cells.
Activation of PERK kinase in neural cells by proteasome inhibitor treatment.
Promastigote to amastigote differentiation of Leishmania is markedly delayed in the absence of PERK …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With…
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ